期刊文献+

盐酸缬更昔洛韦片万赛维的属性剖析

Analysis of properties of valganciclovir hydrochloride tablets
下载PDF
导出
摘要 目的剖析盐酸缬更昔洛韦片万赛维的属性。方法采用观察及测试的方法考察三批盐酸缬更昔洛韦片万赛维的属性差异,对比分析三批盐酸缬更昔洛韦片万赛维在不同介质中的溶出曲线数据。结果三批盐酸缬更昔洛韦片万赛维的含量、有关物质及溶出度无明显差异,批间均一性较好。依照溶出曲线的测定方法,分别测定盐酸缬更昔洛韦片万赛维在4种不同溶出介质中的溶出曲线,其溶出曲线对比显示,三批盐酸缬更昔洛韦片万赛维在不同溶出介质中的溶出曲线数据无明显差异,批间均一性较好。结论盐酸缬更昔洛韦片万赛维不同批次之间重现性较好,批间差异在可接受范围内,各项指标无明显差异,是仿制药品优良的参比制剂,临床上也可以放心使用。 Objective To analyze the properties of valganciclovir hydrochloride tablets.Methods The differences in the properties of the three batches of valganciclovir hydrochloride tablets were investigated by observation and testing,and the dissolution curve data of the three batches of valganciclovir hydrochloride tablets in different media were compared and analyzed.Results There were no significant differences in the content,relevant substances and dissolution rate of the three batches of valganciclovir hydrochloride tablets,and the batch-to-batch uniformity was good.The dissolution curves of valganciclovir hydrochloride tablets in four different dissolution media were measured according to the method of dissolution curve,and the comparison of the dissolution curves showed that there was no significant difference among the three batches of valganciclovir hydrochloride tablets in different dissolution media,and the batch-to-batch uniformity was good.Conclusion Valganciclovir hydrochloride tablets have good reproducibility in different batches,the batch-to-batch variation is within an acceptable range,and there is no significant difference in various indicators.It is an excellent reference preparation for generic drugs and can be used with confidence in clinical practice.
作者 刘艳红 邓霞飞 唐维 刘红华 方智 张茜 刘澍秾 郭峰 LIU Yan-hong;DENG Xia-fei;Tang Wei(Wuhan Renfu Pharmaceutical Co.,Ltd.,Wuhan 430206,China)
出处 《中国现代药物应用》 2022年第14期191-194,共4页 Chinese Journal of Modern Drug Application
关键词 盐酸缬更昔洛韦片 属性剖析 批间差异 Valganciclovir hydrochloride tablets Propertie analysis Batch difference
  • 相关文献

参考文献3

二级参考文献14

  • 1侯舒,王亚亭.抗人巨细胞病毒药物及其治疗研究进展[J].国外医学(儿科学分册),2004,31(5):234-237. 被引量:6
  • 2李艳萍,李卓荣,山广志.抗病毒药物缬更昔洛韦的合成研究[J].中国抗生素杂志,2005,30(6):336-337. 被引量:5
  • 3Clercq ED.New inhibitors of human cytomegalovirus(HCMV) on the horizon[J].JAntimicrob Chemother,2003,51(5):1079-1083.
  • 4Cvetkovic RS,Wellington K.Valganciclovir:a review of its use in the management of CMV infection and disease in immunocompromised patients[J].Drugs,2005,65(6):859-878.
  • 5Paya C,Humar A,Dominguez E,et al.Efficacy and safety of valganciclovir vs.oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients[J].Am J Transplant,2004,4(4):611-620.
  • 6Maag H,Nestor JJ,Womble SW,et al.2-(2-Amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative:US,6083953[P].2000-07-04.
  • 7Dvorak CA,Wren DL,Fisher LE,et al.Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative:US,6040446[P].2000-03-21.
  • 8Arzeno HB,Beard CC,Fisher LE,et al.Process for preparing purine derivatives:WO,1997027194[P].1997-07-31.
  • 9Arzeno HB,Humphreys ER,Bruno S,et al.Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl)-methoxy-1,3-propanediol derivative:US,5756736[P].1998-05-26.
  • 10Babu KS,Srinivas P,Madhavi YV,et al.A succinct synthesis of valganciclovir hydmchloride,a cytomegalovims(CMV)retinitis inhibitor[J].Arkivoc,2011,(2):199-208.

共引文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部